King's College London

Research portal

Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management

Research output: Contribution to journalArticlepeer-review

Sandy Feng, John C. Bucuvalas, George V. Mazariegos, John C. Magee, Alberto Sanchez-Fueyo, Katharine M. Spain, Andrew Lesniak, Sai Kanaparthi, Emily Perito, Veena L. Venkat, Bryna E. Burrell, Estella M. Alonso, Nancy D. Bridges, Edward Doo, Nitika A. Gupta, Ryan W. Himes, David Ikle, Annette M. Jackson, Steven J. Lobritto, Juan Jose Lozano & 8 more Mercedes Martinez, Vicky L. Ng, Elizabeth B. Rand, Averell H. Sherker, Shikha S. Sundaram, Yumirle P. Turmelle, Michele Wood-Trageser, Anthony J. Demetris

Original languageEnglish
Pages (from-to)1985-2004
Number of pages20
Issue number5
PublishedMay 2021

Bibliographical note

Funding Information: The authors are grateful to the patients and their families who participated in the study. We thank Allison Priore, Sharon Blaschka, RN, FNP, and Andre Hawkins for their extensive contributions to the management and conduct of the trial, and Kalpana Harish, M.P.H., for expert grants administration. We thank all of the co-investigators and research coordinators. Finally, we are indebted to Deborah Phippard, Ph.D., and Allan Kirk, M.D., for their wise guidance, particularly during the planning phase of the trial. Publisher Copyright: © 2020 by the American Association for the Study of Liver Diseases. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors


Background and Aims: Tolerance is transplantation’s holy grail, as it denotes allograft health without immunosuppression and its toxicities. Our aim was to determine, among stable long-term pediatric liver transplant recipients, the efficacy and safety of immunosuppression withdrawal to identify operational tolerance. Approach and Results: We conducted a multicenter, single-arm trial of immunosuppression withdrawal over 36-48 weeks. Liver tests were monitored biweekly (year 1), monthly (year 2), and bimonthly (years 3-4). For-cause biopsies were done at investigators’ discretion but mandated when alanine aminotransferase or gamma glutamyltransferase exceeded 100 U/L. All subjects underwent final liver biopsy at trial end. The primary efficacy endpoint was operational tolerance, defined by strict biochemical and histological criteria 1 year after stopping immunosuppression. Among 88 subjects (median age 11 years; 39 boys; 57 deceased donor grafts), 33 (37.5%; 95% confidence interval [CI] 27.4%, 48.5%) were operationally tolerant, 16 were nontolerant by histology (met biochemical but failed histological criteria), and 39 were nontolerant by rejection. Rejection, predicted by subtle liver inflammation in trial entry biopsies, typically (n = 32) occurred at ≤32% of the trial-entry immunosuppression dose and was treated with corticosteroids (n = 32) and/or tacrolimus (n = 38) with resolution (liver tests within 1.5 times the baseline) for all but 1 subject. No death, graft loss, or chronic, severe, or refractory rejection occurred. Neither fibrosis stage nor the expression level of a rejection gene set increased over 4 years for either tolerant or nontolerant subjects. Conclusions: Immunosuppression withdrawal showed that 37.5% of selected pediatric liver-transplant recipients were operationally tolerant. Allograft histology did not deteriorate for either tolerant or nontolerant subjects. The timing and reversibility of failed withdrawal justifies future trials exploring the efficacy, safety, and potential benefits of immunosuppression minimization.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454